Abbott Laboratories (NYSE:ABT) reported its Q3 2024 earnings, meeting EPS expectations while slightly missing revenue forecasts. The company posted an EPS of $1.34, aligning with analysts' predictions ...

In the past few years, some high-profile dividend stocks have reduced their payouts, much to the chagrin of investors. As ...

Abbott (NYSE:ABT) today unveiled a new initiative addressing the biases and stigmas associated with diabetes management.

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

Abbott Laboratories is a well-diversified health care company, with four distinct units: medical devices, diagnostics, ...

Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes Care and Medical Devices.

Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.

Abbott Laboratories (NYSE: ABT) is a well-diversified health care company, with four distinct units: medical devices, ...